CD44 and cancer: Our previous work has shown that even though nal‐IRI alone treatment does enrich CD44 cancer stem‐like cell subpopulations, it does significantly reduce overall metastatic burden with respect to untreated mice.[17] This effect is not surprising, as nal‐IRI is currently approved for PDAC patients and has been shown to significantly extend patient survival.